Management of heart failure with pulmonary hypertension

Current Cardiology Reports

Volumn 7, Issue 3, 2005, Pages 196-203

  Osman, Mohammed Najeeb ^b   Dunlap, Mark E ^a  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMBRISENTAN; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGOXIN; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FLUOXETINE; ILOPROST; NIFEDIPINE; NITRATE; NITRIC OXIDE; NITRIC OXIDE DONOR; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TREPOSTINIL; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASODILATOR AGENT; WARFARIN;

BALLOON DILATATION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC TEST; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EMBOLECTOMY; ENDARTERECTOMY; EXERCISE TEST; FLUSHING; HEADACHE; HEART DISEASE; HEART FAILURE; HEART LEFT RIGHT SHUNT; HEART LEFT VENTRICLE CONTRACTION; HEART LUNG TRANSPLANTATION; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; LIVER TOXICITY; LUNG DISEASE; LUNG EMBOLISM; MEDICAL DECISION MAKING; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SYMPOSIUM; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 23844552809     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-005-0077-4     Document Type: Review

References (58)

1. Colucci WS, Braunwald E: Pathophysiology of heart failure.In Heart Disease: A Textbook of Cardiovascular Medicine, edn 5. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:394.
2. Macnee W: Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part one. Am J Respir Crit Care Med 1994, 150:833-852.
3. Fishman AP: Induction to the national registry on primary pulmonary hypertension. In The Pulmonary Circulation: Normal and Abnormal. Mechanisms, Management and the National Registry. Edited by Fishman AP. Philadelphia: University of Pennsylvania; 1990:343-352.
4. Rich S, Rubin LJ, Abenhail L, et al.: Executive summary from the World Symposium on Primary Pulmonary Hypertension The World Health Organization. Evian, France; September 6-10, 1998. http://www.who.int/ncd/cvd/pph.html
5. Simonneau G, Galie N, Rubin J, et al.: Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):5S-12S.
6. Wagenvoort CA: Pathology of Pulmonary Hypertension. New York: John Wiley, 1977:217-231.
7. Saad EB, Marrouche NE, Saad CP, et al.: Pulmonary vein stenosis after radiofrequency ablation of atrial fibrillation: functional characterization, evolution, and influence of the ablation strategy. Circulation 2003, 108:3102-3107.
8. Schwartzman D, Kanzaki H, Bazaz R, et al.: Impact of catheter ablation on pulmonary vein morphology and mechanical function. J Cardiovasc Electrophysiol 2004, 15:161-167.
9. Yataco J, Stoller JK: Pulmonary venous thrombosis and infarction complicating pulmonary venous stenosis following radiofrequency ablation. Respir Care 2004, 49:1525-1527.
10. Leatham A: The second heart sound. Key to auscultation of the heart. Acta Cardiol 1964, 19:395-416.
11. Wood P: The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J 1958, 46:755-762.
12. Somerville J: Paul Wood Lecture. The master's legacy: the first Paul Wood Lecture. Heart 1998, 80:612-619.
13. O'Rourke RA, Shaver JA, Salemi R, et al.: The history, physical examination and cardiac auscultation. In Hurst's the Heart Arteries and Veins, edn 9. Edited by Alexander RW, Schlant RC, Fuster V. New York: McGraw-Hill; 1998:292.
14. Ahearn GS, Tapson VF, Rebeiz A, et al.: Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002, 122:524-527.
15. Ferrari E, Imbert A, Chevalier P, et al.: The EGG in pulmonary embolism. Predictive value of negative T waves in precordial leads-80 case reports. Chest 1997, 111:537-543.
16. Rodger M, Makropulos D, Turek M, et al.: Diagnostic value of the electrocardiogram in suspected pulmonary embolism. Am J Cardiol 2000, 86:807-809, A10.
17. Stein PD, Saltzman HA, Weg JG: Clinical characteristics of patients with acute pulmonary embolism. Am J Cardiol 1991, 68:1723-1724.
18. Milne EN, Pistolesi M, Miniati M, et al.: The radiologic distinction of cardiogenic and noncardiogenic edema. AJR Am J Roentgenol 1985, 144:879-894.
19. Steiner RM, Levin DC: Radiology of the heart and great vessels. In Heart Disease: A Textbook of Cardiovascular Medicine, edn 5. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:218-219.
20. Thomas JD, Weyman AE: Echocardiographic Doppler evaluation of left ventricular diastolic function. Physics and physiology. Circulation 1991, 84:977-990.
21. Isobe M, Yazaki Y, Takaku F, et al.: Prediction of pulmonary arterial pressure in adults by pulsed Doppler echocardiography. Am J Cardiol 1986, 57:316-321.
22. Van Hare GF, Silverman NH: Contrast two-dimensional echocardiography in congenital heart disease: techniques, indications and clinical utility. J Am Coll Cardiol 1989, 13:673-686.
23. Barst RJ, McGoon M, Torbicki A, et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):40S-47S.
24. Bady E, Achkar A, Pascal S, et al.: Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000, 55:934-939.
25. Moser K, Bloor C: Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993, 103:685-692.
26. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
27. Hodgkin JE: Prognosis in chronic obstructive pulmonary disease. Clin Chest Med 1990, 11:555-569.
28. Barst RJ, Rubin LJ, Long WA, et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334:296-302.
29. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
30. Nagaya N, Uematsu M, Satoh T, et al.: Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:487-492.
31. Nagaya N, Nishikimi T, Uematsu M, et al.: Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
32. Robbins IM, Christman BW, Newman JH, et al.: A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998, 114:1269-1275.
33. Alchanatis, Tourkohoriti G, Kakouros S, et al.: Daytime pulmonary hypertension in patients with obstructive sleep apnea: the effect of continuous positive airway pressure on pulmonary hemodynamics. Respiration 2001, 68:566-572.
34. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal oxygen therapy trial group. Ann Intern Med 1980, 93:391-398.
35. Redfield M, Jacobsen SJ, Burnett JC, et al.: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
36. Rich S, Braunwald E, Grossman W: Pulmonary hypertension. In Heart Disease: A Textbook of Cardiovascular Medicine, edn 5. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:797.
37. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997, 336:525-533.
38. Shaffer EM, Rocchini AP, Spicer RL, et al.: Effects of verapamil on left ventricular diastolic filling in children with hypertrophic cardiomyopathy. Am J Cardiol 1988, 61:413-417.
39. Yamakado T, Okano H, Higashiyama S, et al.: Effects of nifedipine on left ventricular diastolic function in patients with asymptomatic or minimally symptomatic hypertrophic cardiomyopathy. Circulation 1990, 81:593-601.
40. Young JB, Dunlap ME, Pfeffer MA, et al.: Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626.
41. Humbert M, Morrell NW, Archer SL, et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl S):13S-24S.
42. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004, 351:1425-1436.
43. Rich S, Kauffman E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992, 327:76-81.
44. Sitbon O, Humbert M, Jagot JL, et al.: Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998, 12:265-270.
45. Badesch DB, Tapson VF, McGoon MD, et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000, 132:425-434.
46. Simonneau G, Barst RJ, Galie N, et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
47. Vachiery JL, Hill N, Zwicke D, et al.: Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002, 121:1561-1565.
48. Hoeper MM, Schwarze M, Ehlerding S, et al.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000, 342:1866-1870.
49. Barst RJ, McGoon M, McLaughlin V, et al.: Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:2119-2125.
50. Channik RN, Simonneau G, Sitbon O, et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
51. Sitbon O, Badesch DB, Channik RN, et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003, 124:247-254.
52. Sastry BK Narasimhan C, Reddy NK, et al.: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004, 43:1149-1153.
53. Humbert M, Barst RJ, Robbins IM, et al.: Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353-359.
54. Galie N, Seeger W, Naeije R, et al.: Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl. S):81S-88S.
55. Archibald CJ, Auger WR, Fedullo PF, et al.: Long-term outcome after pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1999, 160:523-528.
56. Sandoval J, Gasper J, Pulido T, et al.: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998, 32:297-304.
57. Pielsticker EJ, Martinez FJ, Rubenfire M: Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 2001, 20:1297-1304.
58. Deng Z, Morse JH, Slager SL, et al.: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67:737-744.